TRAP Trial - Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients. (TRAP)
We are delighted to invite you to our next webinar with Dr Alison Tree, to give a presentation on her research work the TRAP trial based at The Royal Marsden Hospital.
This multi-centre, phase II trial is being conducted in men with castration resistant prostate cancer. The aim of the TRAP trial is to test whether a new precise radiotherapy technique called stereotactic body radiotherapy (SBRT) can slow down the growth of metastatic prostate cancer. If SBRT is effective it will represent a new treatment option in these patients, providing more prolonged control without having to resort to chemotherapy and its potentially unpleasant side effects.
When: Nov 23, 2020 06:30 PM London
Topic: TRAP Trial - Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients. (TRAP)
Register in advance for this webinar:
https://prostatecanceruk.zoom.us/webinar/register/WN_yg85w6krTmScIwip0IzjFA
After registering, you will receive a confirmation email containing information about joining the webinar.
----------
Webinar Speakers
Alison Tree (Doctor @Institute of Cancer Research)
Alison Tree was appointed as a consultant clinical oncologist at the Royal Marsden hospital in 2014, specialising in urological malignancies. She holds an Associate Honorary Faculty position at the Institute of Cancer Research. Her MD thesis was on stereotactic radiotherapy techniques for prostate and oligometastatic cancer.
She is on the NCRI Prostate CSG committee, the UK SABR consortium committee and the editorial board of Clinical Oncology. She is CI of the TRAP, DELINEATE and PRISM studies, lead for the PACE C trial and co-investigator of the PIVOTALboost and InPACT trials. Her research has received funding from Prostate Cancer UK, Cancer Research UK, the Rosetrees Trust, the JP Moulton foundation, and Elekta. She is prostate lead for the MR Linac consortium. Her current research interests include technical radiotherapy improvements in localised prostate cancer, oligometastatic and oligoprogressive disease.
Edited by member 10 Nov 2020 at 13:44
| Reason: Not specified